Johanne Kaplan bought $30k of PMN
Chief Development Officer at ProMIS Neurosciences Inc.. 2,280 shares at an average of $13.30, traded Aug 5, 2026, filed Aug 7, 2026.
Score components
- +15RoleOfficer
- +5Trade size$30k at market
- +10Relative to holdingsHoldings up 58%
- +8Price context46% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-092673, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | POpen-market purchase Common Shares | +2,280 | $13.30 | $30k | 6,221 | Aug 7, 2026 |
Related signals
Other insiders at ProMIS Neurosciences Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | PMNbuy ProMIS Neurosciences Inc. | Patrick D. Kirwin director | $45k 4,000 shares | +613% | |
| 38Weak | ProMIS Neurosciences Inc. | Eugene Williams director | $49k 2,000 shares | +19% | |
| 46Moderate | ProMIS Neurosciences Inc. | Eugene Williams director | $92k 4,000 shares | +63% | |
| 46Moderate | ProMIS Neurosciences Inc. | Johanne Kaplan Chief Development Officer | $25k 1,629 shares | +70% | |
| 58Moderate | PMNbuy ProMIS Neurosciences Inc. | Slanix Paul Alex director | $8.5M 700,741 shares | +289% | |
| 26Weak | PMNbuy ProMIS Neurosciences Inc. | Max A. Milbury Principal Accounting Officer | $15k 30,392 shares | +203% | |
| 25Weak | PMNbuy ProMIS Neurosciences Inc. | Neil Cashman Chief Scientific Officer | $15k 15,000 shares | +928% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.